← Back to Patent Explorer
US4885167A Expired / Lapsed US ⏱️ 0.0 years remaining

Restoration of impaired cardiac function of patients with diverse muscular dystrophies by therapy with coenzyme Q10

Assignee: The University of Texas System
•
Filing: 1988-02-16
•
Granted: 1989-12-05
•
Expires: 2008-02-16
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The present invention relates to the use of Coenzyme Q in the treatment of slow muscle degeneration, commonly known to those of skill in the art so a dystrophy or atrophy, and the accompanying cardiac complications typically identified in such patients. Administration of Coenzyme Q, and particularly the analog Coenzyme Q10 (CoQ10) to humans increases the pumping of blood by the heart, and thereby increases tissue oxygeneration throughout the body. The net physiological effect halts the progression of muscle deterioration and improves cardiac function. An overall improvement in the quality of life for these human subjects is also observed, said patients reportedly experiencing less fatigue. A method for treating human patients with progressive muscular dystrophies or the neurogenic atrophies with Coenzyme Q10 (CoQ10) specifically disclosed. The method is similarly effective for the treatment of any form of muscle degeneration or cardiac muscular dysfunction independently.

Inventors

  • 👤 Karl Folkers
  • 👤 Janusz Wolaniuk

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-05 17:37
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/12; A61K31/122

Claims Analysis

Total Claims: 2
Claim 1
Independent Claim 66 words
A method for treating impaired cardiac function of human patients having the Duchenne dystrophy, the Becker dystrophy, the limb-girdle dystrophies, myotonic dystrophy, Charcot-Marie-Tooth disease fascioscapulohumoral muscular disease, hypotonia congenitale or Welander disease, or a closely related disease, said method comprising administering to the patients having any one of these dystrophies or myopathies a therapeutically effective amount of a formulation consisting essentially of coenzyme Q 10 .
Claim 2
Independent Claim 66 words
A method for treating impaired cardiac function of human patients having the Duchenne dystrophy, the Becker dystrophy, the limb-girdle dystrophies, myotonic dystrophy, Charcot-Marie-Tooth disease fascioscapulohumoral muscular disease, hypotonia congenitale or Welander disease, or a closely related disease, said method comprising administering to the patients having any one of these dystrophies or myopathies a therapeutically effective amount of a formulation consisting essentially of coenzyme Q 10 .

References Cited (Backward Citations)

US4068003A Cited
US4156718A Cited
US4491594A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1992-12-04 1993-06-05 1993-12-05 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1996-12-04 1997-06-05 1997-12-05 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2000-12-04 2001-06-05 2001-12-05 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag